Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65 inclusive~* Male, non-child-bearing female or fertile female with appropriate contraception.~* Mild to moderate confirmed active ulcerative colitis~* Able and willing to give informed consent~Exclusion Criteria:~* Colitis of other cause~* Pregnancy, inadequate contraception for fertile female patients~* Liver or kidney disease, unstable cardiovascular disease, coagulation disorder.~* Other significant medical condition that preclude participation at investigator criteria~* Allergy or hypersensitivity to salicylates~* Previous or concomitant treatment for ulcerative colitis interfering with safety or activity assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dersalazine (Type: EXPERIMENTAL): None
- Mesalazine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).